IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.884
AS - Asia 4.928
EU - Europa 3.981
SA - Sud America 669
AF - Africa 279
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.756
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.745
SG - Singapore 1.658
CN - Cina 1.385
IT - Italia 1.158
VN - Vietnam 783
IE - Irlanda 574
SE - Svezia 534
BR - Brasile 515
FI - Finlandia 422
DE - Germania 348
HK - Hong Kong 347
BD - Bangladesh 191
FR - Francia 187
ZA - Sudafrica 160
UA - Ucraina 155
NL - Olanda 150
GB - Regno Unito 118
IN - India 115
TR - Turchia 109
CA - Canada 88
RU - Federazione Russa 82
AT - Austria 65
CI - Costa d'Avorio 62
AR - Argentina 61
BE - Belgio 47
JP - Giappone 42
ID - Indonesia 36
PL - Polonia 34
IQ - Iraq 32
KR - Corea 32
MX - Messico 27
CO - Colombia 25
ES - Italia 25
PK - Pakistan 25
PH - Filippine 24
EC - Ecuador 23
CZ - Repubblica Ceca 19
TH - Thailandia 19
SA - Arabia Saudita 15
MA - Marocco 14
IR - Iran 13
UZ - Uzbekistan 13
CL - Cile 12
KE - Kenya 11
LT - Lituania 11
VE - Venezuela 11
HU - Ungheria 9
MY - Malesia 8
TW - Taiwan 8
AU - Australia 7
JO - Giordania 7
PY - Paraguay 7
SY - Repubblica araba siriana 7
TN - Tunisia 7
AL - Albania 6
DZ - Algeria 6
LU - Lussemburgo 6
NP - Nepal 6
PS - Palestinian Territory 6
RO - Romania 6
UY - Uruguay 6
AZ - Azerbaigian 5
BO - Bolivia 5
EG - Egitto 5
KG - Kirghizistan 5
OM - Oman 5
CH - Svizzera 4
IL - Israele 4
JM - Giamaica 4
NZ - Nuova Zelanda 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
MD - Moldavia 3
PA - Panama 3
SI - Slovenia 3
BB - Barbados 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
NI - Nicaragua 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
Totale 15.736
Salva come PNG Salva come JPEG
Città #
Singapore 877
Ashburn 631
Dallas 622
Dublin 573
San Jose 503
Chandler 499
Santa Clara 330
Parma 325
Hong Kong 322
Beijing 318
Ann Arbor 314
Ho Chi Minh City 231
Boardman 187
Jacksonville 187
Dearborn 167
Hanoi 154
Johannesburg 152
Los Angeles 152
New York 147
Nanjing 119
Shanghai 115
Munich 107
Chicago 105
Lauterbourg 98
Council Bluffs 94
Princeton 89
Milan 88
Hefei 87
Izmir 82
Abidjan 62
Wilmington 57
Bremen 56
San Mateo 55
Bologna 54
Buffalo 53
Nanchang 51
São Paulo 51
Vienna 50
Kunming 48
Helsinki 47
Shenyang 47
Rome 41
Haiphong 40
Toronto 39
Tianjin 38
Marseille 35
Brussels 30
Modena 30
Seattle 30
Columbus 29
Da Nang 29
Des Moines 29
Guangzhou 29
Hebei 29
Jinan 29
Jakarta 28
Moscow 28
Turku 26
Warsaw 26
London 24
Tokyo 24
Frankfurt am Main 23
Pune 23
Reggio Emilia 23
The Dalles 23
Denver 22
Changsha 21
Grafing 21
Houston 21
Nuremberg 21
Woodbridge 21
Amsterdam 20
Phoenix 20
Seoul 20
Brooklyn 19
Levanto 19
Norwalk 19
Redmond 19
Rio de Janeiro 19
Jiaxing 17
Stockholm 17
Montreal 16
Atlanta 15
Fremont 15
Orem 15
Manchester 14
Boston 13
Brasília 13
Brescia 13
Chennai 13
Hải Dương 13
Leawood 13
Bari 12
Florence 12
San Francisco 12
Tashkent 12
Verona 12
Wayne 12
Baghdad 11
Belo Horizonte 11
Totale 9.574
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 284
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 267
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 251
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 246
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 220
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 207
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 205
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 202
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 198
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 195
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 194
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 194
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 192
Characterization of gefitinib uptake in NSCLC cell lines 190
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 183
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 182
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 178
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 178
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 178
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 176
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 173
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 161
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 161
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 159
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 159
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 158
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
Interaction between occupational radon exposure and tobacco smoke: a systematic review 157
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 156
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 152
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 148
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 148
Synergistic activity of letrozole and sorafenib on breast cancer cells 147
Physico-chemical characterization and biological evaluation of two fibroin materials 145
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 144
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 140
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 140
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 140
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 135
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 135
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 134
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 133
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 130
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 130
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 129
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 129
null 126
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 122
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 121
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 119
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 119
Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions 118
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 118
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 116
Osteopontin is produced by human multiple myeloma cells 116
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 115
Multiple myeloma patient with unusual extramedullary involvement 114
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 113
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 112
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 111
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 111
Multiple myeloma patient with unusual extramedullary involvement 108
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 107
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 107
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 105
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 104
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 103
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 102
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 99
Targeting FGFR1 pathway in squamous cell lung cancer 98
Optimizing EGFR inhibitor treatment in non small cell lung cancer 96
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 96
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 93
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 93
Circulating neural growth factor in pancreatic cancer adenocarcinoma 92
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 91
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 90
RANKL is critically involved in the physiopathology of multiple myeloma 89
Totale 15.085
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.818
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022574 36 15 52 41 20 25 88 50 31 22 40 154
2022/20232.208 211 234 150 141 197 244 45 142 687 17 101 39
2023/20241.003 35 73 34 47 81 185 85 81 44 55 105 178
2024/20252.898 137 136 185 197 279 281 204 144 338 241 261 495
2025/20266.492 517 583 853 585 815 354 690 200 893 450 377 175
2026/2027105 105 0 0 0 0 0 0 0 0 0 0 0
Totale 15.956